Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) (PROMISE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03986138

Recruitment Status : Completed

First Posted : June 14, 2019

Last Update Posted : November 10, 2021

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Guerbet

Results Submitted - Quality Control (QC) Review Has Not Concluded

Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status :	Completed
Actual Primary Completion Date :	December 9, 2020
Actual Study Completion Date :	December 9, 2020
Certification/Extension First Submitted :	May 12, 2021

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	October 24, 2022	November 17, 2022 Submission with QC Comments
2	September 7, 2023	September 27, 2023 Submission with QC Comments
3	November 7, 2023	November 28, 2023 Submission with QC Comments

To Top